印度代谢性非传染性疾病健康报告:ICMR-INDIAB全国横断面研究(ICMR-INDIAB-17)
该研究为印度ICMR-INDIAB全国横断面调查,纳入31个州及联邦属地20岁及以上代表性样本113 043人。结果显示糖尿病加权患病率11.4%、糖尿病前期15.3%、高血压35.5%、全身性肥胖28.6%、腹型肥胖39.5%、血脂异常81.2%,除糖尿病前期外城市均高于农村。作者认为印度代谢性非传染性疾病患病率被严重低估,需制定针对各州的紧急政策与干预。
要点
- 印度糖尿病加权患病率为11.4%,糖尿病前期为15.3%,高血压为35.5%。
- 全身性肥胖为28.6%,腹型肥胖为39.5%,血脂异常为81.2%。
- 除糖尿病前期外,所有代谢性非传染性疾病城市患病率均高于农村。
核心结论
- 印度糖尿病及其他代谢性非传染性疾病患病率显著高于既往估计。
- 糖尿病疫情在较发达州趋于稳定,但在大多数其他州仍在上升。
- 作者认为这对国家有严重影响,需要制定针对各州的紧急政策与干预以遏制代谢性非传染性疾病的快速上升。
研究设计与样本
- 印度医学研究理事会-印度糖尿病(ICMR-INDIAB)研究为横断面人群调查,纳入印度31个州、联邦属地及国家首都辖区城乡20岁及以上代表性样本,采用分层多阶段抽样设计,按地理、人口规模和社会经济状况三级分层,于2008年10月18日至2020年12月17日分多阶段实施。
- 共113 043人参与,其中农村79 506人,城市33 537人。
- 糖尿病和糖尿病前期采用WHO标准诊断,高血压采用第八届联合国家委员会指南,肥胖(全身性和腹型)采用WHO亚太地区指南,血脂异常采用国家胆固醇教育计划-成人治疗小组III指南。
主要发现
- 糖尿病总体加权患病率为11.4%(95%CI 10.2-12.5;107 119人中10 151例)。
- 糖尿病前期总体加权患病率为15.3%(95%CI 13.9-16.6;107 119人中15 496例)。
- 高血压总体加权患病率为35.5%(95%CI 33.8-37.3;111 439人中35 172例)。
- 全身性肥胖总体加权患病率为28.6%(95%CI 26.9-30.3;110 368人中29 861例)。
- 腹型肥胖总体加权患病率为39.5%(95%CI 37.7-41.4;108 665人中40 121例)。
关键数值与推荐
- 糖尿病和糖尿病前期诊断采用WHO标准。
- 高血压诊断采用第八届联合国家委员会指南。
- 肥胖(全身性和腹型)采用WHO亚太地区指南。
- 血脂异常采用国家胆固醇教育计划-成人治疗小组III指南。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-communicable disease (NCD) rates are rapidly increasing in India with wide regional variations. We aimed to quantify the prevalence of metabolic NCDs in India and analyse interstate and inter-regional variations. METHODS: The Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study, a cross-sectional population-based survey, assessed a representative sample of individuals aged 20 years and older drawn from urban and rural areas of 31 states, union territories, and the National Capital Territory of India. We conducted the survey in multiple phases with a stratified multistage sampling design, using three-level stratification based on geography, population size, and socioeconomic status of each state. Diabetes and prediabetes were diagnosed using the WHO criteria, hypertension using the Eighth Joint National Committee guidelines, obesity (generalised and abdominal) using the WHO Asia Pacific guidelines, and dyslipidaemia using the National Cholesterol Education Program-Adult Treatment Panel III guidelines. FINDINGS: A total of 113 043 individuals (79 506 from rural areas and 33 537 from urban areas) participated in the ICMR-INDIAB study between Oct 18, 2008 and Dec 17, 2020. The overall weighted prevalence of diabetes was 11·4% (95% CI 10·2-12·5; 10 151 of 107 119 individuals), prediabetes 15·3% (13·9-16·6; 15 496 of 107 119 individuals), hypertension 35·5% (33·8-37·3; 35 172 of 111 439 individuals), generalised obesity 28·6% (26·9-30·3; 29 861 of 110 368 individuals), abdominal obesity 39·5% (37·7-41·4; 40 121 of 108 665 individuals), and dyslipidaemia 81·2% (77·9-84·5; 14 895 of 18 492 of 25 647). All metabolic NCDs except prediabetes were more frequent in urban than rural areas. In many states with a lower human development index, the ratio of diabetes to prediabetes was less than 1. INTERPRETATION: The prevalence of diabetes and other metabolic NCDs in India is considerably higher than previously estimated. While the diabetes epidemic is stabilising in the more developed states of the country, it is still increasing in most other states. Thus, there are serious implications for the nation, warranting urgent state-specific policies and interventions to arrest the rapidly rising epidemic of metabolic NCDs in India. FUNDING: Indian Council of Medical Research and Department of Health Research, Ministry of Health and Family Welfare, Government of India.
引用
- Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023. PMID: 37301218. doi:10.1016/S2213-8587(23)00119-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。